Drug Makers Find Little Federal Response To CO2 Shortage

Drug stakeholders are raising concerns that it is unclear who in the federal government is responsible for responding to a shortage of carbon dioxide (CO2), a component of the dry ice frequently used for transporting drugs, as scarcity of the gas impacts drug and vaccine access. The White House Office of Science and Technology Policy (OSTP) did not respond to inquiries from Inside Health Policy about whether it is taking action or engaging with stakeholders on the CO2 shortage,...